Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Commercial Officer | August 31, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 31, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,555 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 10,000 · Balance 68,555 Row 2 · 2026-08-31 · Sale · Disposed 10,000 · Balance 58,555 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.26 · Expires 2031-03-31 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-31 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 2, 2026 23:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 885 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-26-000001 · form4.xml · derivative · entry 4 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,772 Underlying: Common Stock · 885 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 885 | $63.16 | $55,896.60 |
DisclosureSEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 885 | $37.63 | $33,302.55 |
DisclosureSEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 913 | $62.09 | $56,688.17 |
DisclosureSEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,809 | $62.44 | $112,953.96 |
DisclosureSEC source: 0001061983-25-000057 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,353 Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 675 | $62.72 | $42,336.00 |
DisclosureSEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,162 F3 · kind: Withholding of shares for tax withholding on vesting of performance shares. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 1,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,837 F2 · kind: Performance shares earned upon achievement of performance goal. Shares remain subject to 1-year vesting requirement. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 1,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,249 F1 · kind: Performance shares earned upon achieving performance goal. Shares vested immediately. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,042 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001061983-25-000049 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,403 Underlying: Common Stock · 1,042 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,042 | $65.96 | $68,730.32 |
DisclosureSEC source: 0001061983-25-000049 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,660 Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,042 | $39.13 | $40,773.46 |
DisclosureSEC source: 0001061983-25-000049 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,628 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 9 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,657 Underlying: Common Stock · 10,628 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,858 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 8 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,857 Underlying: Common Stock · 15,858 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 7 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,445 Underlying: Common Stock · 11,000 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 6 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 52,486 | $65.95 | $3,461,451.70 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 5 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,660 Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,628 | $37.63 | $399,931.64 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 4 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,858 | $37.63 | $596,736.54 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,000 | $39.13 | $430,430.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,368 | $65.02 | $88,947.36 |
DisclosureSEC source: 0001061983-25-000045 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,660 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 8,659 | $32.04 | $277,434.36 |
DisclosureSEC source: 0001127602-25-016865 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,028 Read SEC document |
| May 05, 2025 Filed May 5, 2025 22:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,002 | $36.68 | $146,793.36 |
DisclosureSEC source: 0001127602-25-013404 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,687 Read SEC document |
| April 07, 2025 Filed Apr 7, 2025 21:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,886 | $35.78 | $103,261.08 |
DisclosureSEC source: 0001127602-25-011767 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,689 Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,775 | $44.38 | $123,154.50 |
DisclosureSEC source: 0001127602-25-009712 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,888 F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 20,900 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,900 | $45.14 | $943,426.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,900 | $23.26 | $486,134.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,900 Underlying: Common Stock · 100 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $45.00 | $4,500.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 100 | $23.26 | $2,326.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 47,593 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,593 Underlying: Common Stock · 47,593 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 2,749 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · derivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,749 Underlying: Common Stock · 2,749 shares Expires 2035-03-14 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 32,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,350 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 20:30 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 26,771 | $43.62 | $1,167,751.02 |
DisclosureSEC source: 0001127602-25-009355 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 01:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,341 | $43.27 | $144,565.07 |
DisclosureSEC source: 0001127602-25-008792 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,434 F1 · kind: Sale to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,114 | $42.88 | $47,768.32 |
DisclosureSEC source: 0001127602-25-008316 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,775 F1 · kind: Sale to cover transaction in relation to vesting of restricted stock units. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 3,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,889 F3 · kind: Transaction represents shares of PSUs whose performance condition was satisfied but that remain subject to time-based vesting. These PSUs to vest in full December 3, 2025. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,351 | $51.51 | $69,590.01 |
DisclosureSEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,712 F2 · kind: Transaction represents withholding of shares to satisfy grantee's tax obligations in connection with vesting PSUs. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,063 F1 · kind: Transaction represents gross shares of common stock received by grantee upon vesting of Performance Stock Units ("PSUs"). Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,224 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010517 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,224 Underlying: Common Stock · 1,224 shares Expires 2034-03-14 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2028. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 18,346 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010517 · form4.xml · derivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,346 Underlying: Common Stock · 18,346 shares Expires 2034-03-14 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2028. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 16,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-010517 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,887 F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 5,103 | $66.88 | $341,288.64 |
DisclosureSEC source: 0001127602-24-009010 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,946 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 21:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,202 | $67.68 | $149,031.36 |
DisclosureSEC source: 0001127602-24-009010 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,049 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 47,445 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001127602-23-009282 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,445 Underlying: Common Stock · 47,445 shares Expires 2033-03-06 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 2,555 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001127602-23-009282 · form4.xml · derivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555 Underlying: Common Stock · 2,555 shares Expires 2033-03-06 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009282 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,683 F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,202 | $39.60 | $87,199.20 |
DisclosureSEC source: 0001127602-23-008853 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,683 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on March 2, 2023 and does not represent a sale by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 969 | $44.13 | $42,761.97 |
DisclosureSEC source: 0001127602-23-005915 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,885 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on February 16, 2023 and does not represent a sale by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.